CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a RegistrantItem 2.03.
(d) Exhibits
|
Exhibit No. |
Description |
| 4.1 |
Form of Convertible Promissory Note (incorporated by reference to Exhibit4.1 to the Form8-K filed on June22, 2017). |
| 4.2 |
Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit4.2 to the Form8-K filed on June22, 2017). |
| 4.3 |
Form of Placement Agent Warrant (incorporated by reference to Exhibit4.3 to the Form8-K filed on June22, 2017). |
| 10.1 |
Form of Subscription Agreement (incorporated by reference to Exhibit10.1 to the Form8-K filed on June22, 2017). |
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
